Category: ACN Newswire

HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801)

ROCKVILLE, MD and SHENZHEN, CHINA, June 21, 2024 – (ACN Newswire via SeaPRwire.com) – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will

More

JBM Healthcare Announces FY2024 Annual Results

KEY HIGHLIGHTS Year-on-year revenue increased by 24.6%, totalling HK$648.4 million Adjusted profit attributable to equity shareholders* soared 149.5% to HK$130.5 million The Board recommends a final dividend of HK4.05 cents per share All three business segments exhibited robust growth momentum

More

China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China

Innovative drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets (Lumeblue®) is an oral diagnostic drug, approved by China’s NMPA for enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy. The results of the Phase III clinical trial in

More